Currently, the data sheet indicates that the antigen must be stored at -80ºC.
Pfizer and BioNTech announced this Friday to the American Food and Drug Administration (FDA) results that demonstrate the stability of their coronavirus vaccine when stored. for two weeks at a temperature between -25°C and -15°C. The companies will present this data to the rest of the world’s regulatory agencies “in the coming weeks.”
Currently, the technical data sheet for the vaccine states that it must be stored in an ultra-cold freezer at temperatures between -80ºC and -60ºC for a period of up to 6 months. This creates logistical problems for its transport to areas of the world that are less prepared for these circumstances, such as Africa.
“If approved, this new storage option would offer pharmacies and vaccination centers greater flexibility in how you manage your vaccine supply. We have been continuously conducting stability studies to support commercial-scale production, with the goal of making the vaccine as accessible as possible,” said Pfizer President and CEO Albert Bourla.
As additional data on the stability of their vaccine becomes available, Pfizer and BioNTech anticipate that the shelf life and/or the expiration date “could be extended and the possibility of storing the vaccine at an alternative temperature in the short term could be considered.”